New drug combo targets Hard-to-Treat cancers

NCT ID NCT06697197

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986482 (an experimental drug) given alone or with nivolumab, relatlimab, or bevacizumab
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial (phase 1/2) with a primary focus on safety, so it is too soon to know if the drug will work. The study is small and may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
RECRUITING

Marseille, Bouches-du-Rhône, 13385, France
Clinica Universidad de Navarra
RECRUITING

Pamplona, Navarre, 31008, Spain
Erasmus Medisch Centrum
RECRUITING

Rotterdam, 3015 GD, Netherlands
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITING

Milan, Lombardy, 20133, Italy
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
General Hospital of Athens "Laiko"
RECRUITING

Athens, Attikí, 11527, Greece
Gustave Roussy
RECRUITING

Villejuif, Paris, 94800, France
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, Barcelona [Barcelona], 08035, Spain
Hospital Universitario HM Sanchinarro
RECRUITING

Madrid, 28050, Spain
Istituto Clinico Humanitas
RECRUITING

Rozzano, Milano, 20089, Italy
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Karolinska Universitetssjukhuset Solna
RECRUITING

Solna, Stockholms Län [se-01], 171 64, Sweden
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Local Institution - 0008
NOT_YET_RECRUITING

Aurora, Colorado, 80045, United States
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)
RECRUITING

Amsterdam, North Holland, 1066 CX, Netherlands
Northwell Health/ RJ Zuckerberg Cancer Center
RECRUITING

Lake Success, New York, 11042, United States
Papageorgiou General Hospital of Thessaloniki
RECRUITING

Thessaloniki, Thessaloníki, 564 29, Greece
Rigshospitalet
RECRUITING

Copenhagen, Capital Region, DK-2100, Denmark
The Angeles Clinic and Research Institute - West Los Angeles Office
RECRUITING

Los Angeles, California, 90025, United States
UZ Gent
RECRUITING

Ghent, Oost-Vlaanderen, 9000, Belgium
University of California, Irvine (UCI) Health - UC Irvine Medical Center
RECRUITING

Irvine, California, 92612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.